20 results
8-K
EX-99.2
NRIX
Nurix Therapeutics Inc
26 May 22
Other Events
7:02am
Development
Data to be discussed at Nurix R&D Day at 8:00 a.m. ET today May 26
SAN FRANCISCO, May 26, 2022 (GLOBAL NEWSWIRE) — Nurix Therapeutics … patients at Nurix’s R&D Day, scheduled for May 26th in New York City, and will provide a full clinical update at a future medical conference in the second
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
7 Jul 22
Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update
4:09pm
of several potential expansions. Relevant clinical and biomarker data supporting the decision were presented at the company’s first R&D Day, which … into Nurix’s platform and progress in its targeted protein modulation programs at the company’s first R&D Day. In addition to providing an update
8-K
NRIX
Nurix Therapeutics Inc
26 May 22
Other Events
7:02am
and development day (“R&D Day”). A copy of the Company’s presentation material for the R&D Day is attached as Exhibit 99.1 hereto and is incorporated
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
26 May 22
Other Events
7:02am
Exhibit 99.1 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine R&D Day New York, NY May 26, 2022
Welcome … Scientific Officer DELigase R&D Platform Hans van Houte Financial Snapshot Chief Financial Officer Conclusions Arthur T Sands, MD, PhD President, CEO
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
10 Jan 22
Other Events
7:11am
/PD in mid-2022 DeTIL-0255 Dose first patient in Phase 1 trial in H1 2022 Phase clinical update from safety run in H2 2022 Investor R&D day Planned
10-Q
f7d8gze
14 Oct 20
Quarterly report
4:02pm
8-K
EX-99.1
j0h6tmdh82 7k
8 Jan 24
Regulation FD Disclosure
7:03am
10-K
juwgqjq 8fbz9
16 Feb 21
Annual report
4:11pm
DRS
EX-10.9
646bsylyi99 04
5 May 20
Draft registration statement
12:00am
S-1
EX-10.9
4j1okwq
2 Jul 20
IPO registration
4:04pm
- Prev
- 1
- Next